FDA approves AVI BioPharma's study for Marburg vaccine

AVI BioPharma, Inc., recently received approval from the U.S. Food and Drug Administration for post-exposure prophylaxis studies on a vaccine targeting Marburg virus infection.

The FDA approved AVI BioPharma to begin safety and efficacy studies of the single oligomer vaccine, called AVI-6003, in both humans and non-human primates, according to MSNBC.

In previous trials, AVI BioPharma showed that the drug's efficacy can be attributed to a single component, while a second component, called AVI-7287, does not appear to contribute to the drug's ability to fight Marburg infection.

The studies are to be conducted under a contract provided by the U.S. Department of Defense and managed by the DOD's Joint Project Manager Transformational Medical Technologies Project Management Office, which is a component of the Joint Program Executive Office for Chemical and Biological Defense.

"While we have not seen any toxicity in humans to date with AVI-6003, by removing AVI-7287 we have a simpler development path and may improve the therapeutic window by evaluating a single action agent," AVI BioPharma's President and CEO Chris Garabedian said, MSNBC reports. "We are pleased to be able to explore this single oligomer as a potentially safe and effective treatment against this lethal hemorrhagic fever virus."

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.